ARLINGTON, VA / ACCESSWIRE / October 11, 2016 / Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) will be presenting at this year's The MicroCap Conference on October 24-25 in Philadelphia at the Hotel Monaco, along with 60 other companies in the microcap universe.
The MicroCap Conference is an exclusive event for investors who specialize in small and microcap stocks. It is an opportunity to be introduced to and speak with management at some of the most attractive small companies, learn from various expert panels, and mingle with other microcap investors.
This event is free for private and institutional investors - to learn more, please click here.
About Marinus Pharmaceuticals, Inc.
Marinus Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development of ganaxolone, which offers a new mechanism of action and convenient dosing to improve the lives of patients suffering from epilepsy and neuropsychiatric disorders. Ganaxolone is being developed in three different dose forms (IV, capsule and liquid) intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings. Marinus is focused on evaluating ganaxolone in rare diseases such as status epilepticus and pediatric indications with comorbidities in seizures and behavior disorders such as PCDH19, CDKL5, Lennox-Gastaut Syndrome, and Fragile X Syndrome. For more information visit www.marinuspharma.com.
SOURCE: Marinus Pharmaceuticals
ReleaseID: 446866
